STOUGHTON, Mass., April 23, 2020 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on.
STOUGHTON, Mass., April 07, 2020 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain.
– Achieves GAAP Profitability with $0.5 Million in Net Income in the First Quarter of 2020 – – Non-GAAP Net Income of $31.2 Million in the First Quarter of 2020 – – Xtampza®.
Let's examine two value stocks that can make you richer in May. AbbVie (NYSE: ABBV) is a blue-chip pharmaceutical company trading at just eight times forward earnings. The company's flagship product is Humira, a drug that treats a variety of diseases, such as Crohn's disease, rheumatoid arthritis, and ulcerative colitis.
Collegium Pharmaceutical, Inc. (COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, announced today the closing of its previously announced acquisition of the Nucynta franchise from Assertio Therapeutics, Inc. Jefferies LLC acted as financial advisor to Collegium on the transaction, and Pepper Hamilton LLP served as legal counsel. In support of the Nucynta acquisition, Collegium also announced today the funding of its previously announced $200.0 million senior secured term loan from BioPharma Credit PLC (“loan”) and the closing of its previously announced underwritten public offering of $143.75 million aggregate principal amount of 2.625% convertible senior notes due 2026 (“notes”), which includes the full exercise by the underwriter of an option to purchase an additional $18.75 million in aggregate principal amount of notes to cover over-allotments.
Top Ranked Growth Stocks to Buy for April 1st
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
You are cautioned that such forward-looking statements involve risks and uncertainties, including and without limitation, the impact of the COVID-19 pandemic, the risks that we may not be able to successfully commercialize Xtampza ER and the Nucynta franchise, and that we may incur significant expense and may not prevail in current or future opioid industry litigation and investigation, patent infringement litigation or other litigation pertaining to our products. Thank you, Alex.
Top Ranked Growth Stocks to Buy for March 20th
COLL vs. NBIX: Which Stock Is the Better Value Option?
Q4 2019 Collegium Pharmaceutical Inc Earnings Call
– 2019 Revenue Growth of 6%, Driven by Xtampza ER revenue growth of 51% – – Xtampza® ER Prescriptions Grew 49% in 2019 – – Collegium Guides to Profitability in 2020 – –.
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Collegium (COLL).
STOUGHTON, Mass., Feb. 26, 2020 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain.
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shareholders might be concerned after seeing the share price drop 20% in...
Top Ranked Growth Stocks to Buy for April 6th
Q1 2020 Collegium Pharmaceutical Inc Earnings Call
Collegium Pharmaceutical, Inc. (COLL) today announced the pricing of its offering of $125,000,000 aggregate principal amount of 2.625% convertible senior notes due 2026 (the “notes”) in a public offering registered under the Securities Act of 1933, as amended. Collegium also granted the underwriter of the notes a 30-day option to purchase up to an additional $18,750,000 principal amount of notes solely to cover over-allotments.
AMRX vs. COLL: Which Stock Is the Better Value Option?